Guidance for Industry
Nonclinical Evaluation of
Late Radiation Toxicity of
Therapeutic Radiopharmaceuticals

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

November 2011
Pharmacology and Toxicology
Guidance for Industry
Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals

Additional copies are available from:

Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, rm. 2201
Silver Spring, MD 20993-0002
Tel: 301-796-3400; Fax: 301-847-8714; E-mail: druginfo@fda.hhs.gov

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

November 2011
Pharmacology and Toxicology
# TABLE OF CONTENTS

I. INTRODUCTION ............................................................................................................. 1  
II. BACKGROUND ............................................................................................................. 2  
III. ACUTE VS. LATE RADIATION TOXICITY .............................................................. 3  
IV. NONCLINICAL LATE RADIATION TOXICITY STUDIES .............................................. 4  
   A. Study Goals................................................................................................................. 4  
   B. Study Design............................................................................................................... 5  
      1. Good Laboratory Practices .................................................................................. 5  
      2. Species Selection ................................................................................................. 5  
      3. Timing of Study .................................................................................................... 6  
      4. General Study Design ......................................................................................... 6  
      5. Dose Levels ........................................................................................................... 7  
      6. Clinical Pathology ................................................................................................ 7  
      7. Necropsy and Histopathology ........................................................................... 7  
V. CONCLUSIONS ......................................................................................................... 7  
REFERENCES.................................................................................................................. 9  
GLOSSARY..................................................................................................................... 11
Guidance for Industry¹
Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals

I. INTRODUCTION

The objective of this guidance is to provide recommendations to industry for designing nonclinical late radiation toxicity studies to determine potential late radiation effects of therapeutic radiopharmaceutical agents. The purpose of conducting nonclinical late radiation toxicity studies is to help minimize the risk of late-occurring radiation toxicities in clinical trials of therapeutic radiopharmaceuticals. Because there are other guidances available for conventional nonclinical safety studies,² this guidance focuses solely on late radiation safety concerns that are unique to therapeutic radiopharmaceuticals. These unique safety concerns result from the risk of irreversible late radiation toxicity when these agents deliver high doses of ionizing radiation to normal organs.

This guidance is not intended to address late radiation toxicity of radiobiologials (e.g., radiolabeled monoclonal antibodies). Biotechnology-derived products are excluded for the same reasons articulated in the ICH guidances for industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals and S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.³ This guidance is also not intended to apply to diagnostic radiopharmaceuticals whose low doses are not expected to elicit late radiation toxic effects.

---

¹ This guidance has been prepared by the Late Radiation Toxicity Working Group, which includes representatives from the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.


³ We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs guidance Web page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND

Therapeutic radiopharmaceuticals are typically administered systemically to treat cancer. For cancer therapy with curative intent, the radiation absorbed doses delivered by therapeutic radiopharmaceuticals are comparable to those delivered with external beam radiotherapy (XRT) and are orders of magnitude higher than doses delivered by diagnostic radiopharmaceuticals. At therapeutic doses of radiation, the late radiation toxicities commonly associated with XRT (e.g., renal, pulmonary, neurologic, late bone marrow failures) can also be seen with therapeutic radiopharmaceuticals. With XRT, if the total dose given to an organ is less than its tolerance dose, the probability of symptomatic late radiation toxicity to that organ will be minimal (Perez et al. 2004). This type of toxicity should not be confused with the radiation-induced secondary malignancies for which the risk is known and accepted as unavoidable. The tolerance doses of most human organs for conventionally fractionated XRT are known and are routinely used to direct the administration of XRT at a dose and schedule that minimizes late toxicity. In the FDA’s experience, however, there are few clinical data from which to estimate organ tolerance doses for therapeutic radiopharmaceuticals.

Organ tolerance doses for systemically administered therapeutic radiopharmaceuticals can differ significantly from the published tolerance doses for conventionally fractionated high dose rate XRT. With XRT, the dose received by an organ is determined by its proximity to the primary radiation beam and the tumor. Organs within the primary radiation beam and in close proximity to the tumor are at greatest risk. In the case of systemically administered radiopharmaceuticals, the dose received by each organ is determined primarily by the pharmacokinetics and biodistribution of the radiopharmaceutical agent. In addition, the range and type of the radiations emanating from the source organ are critical.

Radiolabeled drug-based therapy is an emerging and complex field with many potential dose modifying factors such as dose rate and fractionation. Experience with external beam therapy demonstrates that with therapeutic doses of radiation a relatively small percentage change in total dose could lead to a large change in the probability of complications after the tolerance limit of an organ has been reached. The organ tolerance doses for XRT are based on conventionally fractionated high dose rate therapy. Fractionation allows for repair of radiation damage between fractions. In contrast, therapeutic radiopharmaceuticals usually deliver a single dose of radiation at a low dose rate, where damage and repair of that damage occur simultaneously as competing processes. Therefore, organ tolerance doses for systemically administered therapeutic radiopharmaceuticals are not directly comparable to those for XRT. In fact, late radiation toxicity has been observed with therapeutic radiopharmaceuticals at estimated organ doses that were below the XRT tolerance doses for the target organs (Giralt et al. 2003). The entity of low
dose hypersensitivity may account for the discrepancy as could anatomic concentration of isotope not captured in the dosimetry software (Joiner et al. 2001; Marples et al. 2004).

Irreversible late radiation toxicities in the kidneys and bladder were observed in clinical trials with two therapeutic radiopharmaceutical agents where administered doses were estimated based upon external beam tolerance dose limits. In one trial of radiopharmaceutical treatment of multiple myeloma, 30 out of 83 patients developed renal dysfunction. Seven patients developed severe thrombotic microangiopathy (TMA) that required renal dialysis, and five of the seven patients died (Giralt et al. 2003). In a second clinical trial of 36 patients receiving radiopharmaceutical therapy for somatostatin receptor-positive tumors, five patients developed TMA; three of whom progressed to end stage renal failure (Moll et al. 2001). These toxicities were not immediately recognized as complications of the treatment because they did not begin to occur until at least 3 months after radiopharmaceutical therapy. This type of delayed onset is typical of late radiation toxicity.

Therefore, there is a need to gain additional knowledge in this area to support the safe administration of therapeutic radiopharmaceuticals to humans. Because studies in humans would be unethical, the best means to gain insight into this issue is by conducting nonclinical late radiation toxicity studies. These studies will aid in identifying organs at risk and establish a margin of safety for late radiation toxicity. As a result, these studies will help to minimize the risk of late-occurring radiation toxicities in clinical trials of therapeutic radiopharmaceuticals.

III. ACUTE VS. LATE RADIATION TOXICITY

Ionizing radiation causes injury to cells and tissues mainly by damaging nuclear DNA (Hall 2000), although non-DNA targets have been described (Coppes et al. 2005). Most damaged cells continue to function normally until they die while attempting to undergo mitosis. Thus the time frame in which radiation injury becomes clinically apparent is determined in part by cell turnover time.

In organs with a rapid cell turnover (early reacting normal tissue) (e.g., bone marrow, epidermis, small intestine, and oropharyngeal mucosa), symptoms of radiation injury (e.g., bone marrow failure, desquamation, nausea, vomiting and diarrhea, and oral mucositis) appear within days to weeks of an acute dose of radiation. Radiation injury to these organs is called early or acute radiation toxicity and is often self-limiting and reversible. However, in organs with a slow cell turnover rate (late responding normal tissue) (e.g., the brain, spinal cord, heart, lungs, liver, kidneys, bone, and bladder), symptoms of radiation injury (e.g., brain necrosis, paralysis, pericardial and myocardial fibrosis with left ventricular failure, interstitial pneumonitis and pulmonary fibrosis, liver or kidney failure, osteoradionecrosis, and hemorrhagic cystitis) do not occur until after a latency period of several months to years during which relatively normal organ function continues. Radiation injury to these organs is referred to as late radiation toxicity and is usually progressive and irreversible (Yaes 1992; Tubiana et al. 1990; Fajardo et al. 2001).
Because acute radiation toxicity becomes apparent within a short time period after administration, proximity in time to radiation exposure can be used as an important criterion in determining whether the radiopharmaceutical is the cause of a particular complication or adverse effect. Such toxicities will become apparent early in a clinical trial and the trial can be revised or terminated, as appropriate. In contrast, late radiation toxicity in organs such as the kidneys, liver, or central nervous system will not become apparent until months or years after treatment, necessitating longer term follow-up of treated patients.

With XRT, radiation injury is often limited to organs within the radiation beams, because more distant organs receive much lower doses. With radiopharmaceutical therapy, the risk of radiation injury to an organ is determined by both its intrinsic radiosensitivity and the concentration time-activity curve of the agent in that organ. For example, late radiation effects can occur if the kidneys receive a significant radiation absorbed dose from radiopharmaceuticals that are removed from the systemic circulation by glomerular filtration. The kidneys are known to have a relatively low radiation tolerance dose (23 Gray (Gy) for conventionally fractionated XRT); therefore, late radiation nephritis may be a dose-limiting toxicity for many therapeutic radiopharmaceuticals. Although the bladder tolerance dose is considerably higher (65 Gy), hemorrhagic cystitis can occur as a late effect unless the bladder is adequately irrigated to reduce residency time.

We believe that currently accepted methods, including software, for estimating radiation dose to specific tissue or organs may be acceptable for diagnostic amounts of radiopharmaceuticals. However, because the need for dose accuracy is higher for the determination of radiation doses for radiotherapeutic purposes, we consider these methods when used alone to be insufficient.

IV. NONCLINICAL LATE RADIATION TOXICITY STUDIES

A. Study Goals

For treatment with therapeutic radiopharmaceuticals with curative intent, radiation absorbed doses comparable to doses delivered by XRT must be delivered to the tumor. Because similarly high doses may be unavoidably delivered to normal tissue, radiation toxicities commonly associated with XRT may also be seen with radiopharmaceutical therapy. Because the prescribed radioactivity is given with a small mass dose of the carrier, radiation toxicity, rather than pharmacological toxicity associated with the cold (nonradioactive) drug substance (formulation), is often dose-limiting. In the past, nonclinical toxicity studies have been conducted mainly with the cold formulation. Although these studies usually have shown that the no observable adverse effect levels (NOAELs) are many times the clinical mass dose, such studies assess the toxicity of the cold formulation only. Therefore, to assess the potential risk of late radiation toxicity in humans, it is important to conduct late radiation toxicity studies in animals. Such studies may allow the sponsor to:

- Perform controlled experiments that are not ethically feasible in humans
- Identify organs at risk for late radiation toxicity
Contains Nonbinding Recommendations

- Establish a NOAEL for late-occurring, irreversible radiation effects in an appropriate animal species, to help select the clinical doses
- Compare the biological effects and tolerance doses of radiation delivered with radiopharmaceutical therapy to those of radiation delivered by XRT in specific organs
- Examine the pathologic changes and possible mechanism of injury
- Distinguish the toxicity of radiopharmaceutical therapy from that of other concomitant therapies
- Determine the amount of organ sparing that could be obtained by fractionating the radiopharmaceutical dose

B. Study Design

There are challenges associated with the design and conduct of nonclinical late radiation toxicity studies. Therapeutic doses of radiopharmaceuticals require the administration of large amounts of radioactivity. The animals and animal waste will be radioactive, requiring radiation precautions to protect personnel and the general public. Precautions will also be necessary for the disposal of radioactive waste. Despite these challenges, such studies have been conducted, and are recommended to optimize dosing and thus ensure safe clinical trials and patient care. Before initiating late radiation toxicity studies, the sponsor should discuss the specifics of the study design with the applicable review division and consider the following factors.

1. Good Laboratory Practices

Late radiation toxicity studies conducted for the safety evaluation of a radiopharmaceutical drug product should be conducted in accordance with pre-existing requirements under the regulations for good laboratory practices (21 CFR part 58) and the Animal Welfare Act (7 U.S.C. 2131 et seq.).

2. Species Selection

The sponsor should take into consideration the similarity in dosimetry, biodistribution, and pharmacokinetic profile of the radiopharmaceutical in the selected species and in humans. Suitable animal models to study late radiation toxicity are available. In published studies, rats (Moulder et al. 1998; Moulder and Fish 1989; Molteni et al. 2000) and dogs (Prescott et al. 1990; McChesney et al. 1989) have been shown to develop late radiation nephropathy and pulmonary fibrosis after external beam irradiation. Radiation-induced myocardial fibrosis has been shown to occur in rabbits (Fajardo and Stewart 1973) and dogs (Gavin and Gillette 1982). The sponsors should discuss with the applicable review division alternative developmental programs when appropriate animal models are not available to study late radiation toxicity.
3. **Timing of Study**

We recommend that the animal studies be scheduled to facilitate the conduct of clinical trials, including the selection of appropriate safety monitoring methods based on findings in such studies. To select the most appropriate species, human dosimetry and pharmacokinetic data using tracer doses should be obtained before initiation of the late radiation toxicity study. Several factors should be considered when assessing the relevance and the timing of the nonclinical studies: (1) the availability of human data following sufficient long-term follow-up in treated patients might obviate the need for such studies; and (2) the recognition that therapeutic radiopharmaceuticals are sometimes developed to treat patients with no other viable treatment options or for patients who will not survive long enough to be affected by late radiation toxicity. Ideally, the studies should be completed before the start of phase 2 dose escalation clinical trials, because late radiation toxicity may not be seen in the first dose cohort until after the entire trial has been completed. However, a phase 2 trial can, based on risk-benefit considerations, be initiated before completion of the late radiation toxicity study.

4. **General Study Design**

The study design should capture acute (occurring within the first few weeks after irradiation) as well as delayed (occurring after a prolonged latency) radiation effects. Clinically, late radiation toxicity is not observed until at least several months to years following the radiotherapy. In animals, late radiation toxicity usually occurs on a shorter timescale than in humans. For example, the latent period for radiation nephritis in rats ranges from 3 to 7 months. In dogs, renal dysfunction is observed by 10 months. Therefore, to obtain a reasonable estimate of the incidence of specific adverse effects, animals should be monitored for late radiation toxicity for at least 1 year after dosing.

To the extent feasible, the nonclinical study design should closely mimic the design of the anticipated clinical trials including similar amount of injected radioactivity, number of doses, frequency of dosing, and dosing interval, as well as the relative tissue turnover rate and the relative biodistribution and pharmacokinetics in the animal species and human. If both single and fractionated dosing will be studied in clinical trials, a two-arm study design evaluating late radiation toxicity after single as well as fractionated dosing may be necessary. If planned radiation doses in humans will require hematopoietic growth factor support or bone marrow rescue, it may be necessary to support or rescue the irradiated animals so that they will survive comparable doses to allow for late radiation toxicity observations.

Parameters that should be monitored are similar to those evaluated in expanded single- or repeat-dose toxicity studies. These parameters include clinical observations, food consumption, body weight, ophthalmologic examination, hematology, clinical chemistry, urinalysis, and postmortem investigations (e.g., necropsy, organ weights, macroscopic and microscopic examinations).
5. **Dose Levels**

Late radiation toxicity studies in animals should include at least four dose levels to identify the NOAEL and dose-related mild-to-severe late radiation toxicity. The study should also include the cold formulation (ideally, the cold isotope equivalent to the highest mass dose) as a control group to distinguish specific radiation effects from potential pharmacological effects of the cold formulation. The dose-limiting toxicities will be severe but are usually reversible (e.g., acute radiation toxicity related to the gastrointestinal tract, bone marrow). Therefore, the highest dose selected should produce acute radiation toxicity. This dose should be at least twice the maximum planned human dose or radiation tolerance dose for the critical organ (TD5/5 external beam radiation) identified as a possible dose-limiting factor in clinical trials. The dose-multiples should be expressed in terms of body surface area and radiation absorbed dose to the critical organs, when critical organs have been identified. The number of animals in each group should be sufficient to ensure survival of an adequate number to perform proper analysis at the completion of study.

6. **Clinical Pathology**

Hematology, urinalysis, and clinical chemistries should be performed before dosing, 2 weeks after dosing, then once every 3 months afterward and at termination. In addition to a standard battery of hematology and clinical chemistry parameters, the study should also include the assessment of relevant biomarkers, if available, to identify late radiation toxicity for the target organ. For example, urinary glutathione-S-transferase isoenzyme levels can be monitored in addition to blood urea nitrogen and creatinine levels as markers for renal injury. We recommend that the study design be developed in consultation with the FDA to ensure that appropriate long-term toxicity indices are monitored.

7. **Necropsy and Histopathology**

Necropsy, including organ weights and macroscopic examination of various organs, should be performed for all animals in the study, including those that died during the study observation period. Detailed histopathologic and microscopic evaluation should be performed at termination.

V. **CONCLUSIONS**

Late radiation toxicity has been observed when the radiation absorbed doses from radiopharmaceuticals were based on external beam organ tolerance dose limits. This is because the determinants for estimating the tolerance doses for the two radiation therapies are different. Therefore, there is a clear need to gain additional knowledge in this area to support the safe administration of these drug products. Because studies in humans would be unethical, the best means to gain insight into the potential irreversible late radiation toxicity with these drug products is by conducting nonclinical toxicity studies. These studies will aid in identifying at-risk organs, establish a margin of safety for late radiation toxicity, quantify potential organ sparing when dose fractionation is used, and compare organ tolerance doses for
radiopharmaceutical therapy to the published tolerance doses for conventionally fractionated high dose rate radiotherapy.

Ideally, radiation toxicity studies in animals should be completed and analyzed before phase 2 dose escalation toxicity trials are initiated in patients. Until we have a better understanding of tolerance doses for radiopharmaceutical therapy, the safest way to proceed is to prescribe individualized doses to patients.
**REFERENCES**


Fajardo, LF and JR Stewart, 1973, Pathogenesis of Radiation-Induced Myocardial Fibrosis, Lab Invest, 29:244-257.


Giralt, S, W Bensinger, M Goodman, D Podoloff, J Eary et al., 2003, $^{166}$Ho-DOTMP Plus Melphalan Followed by Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma: Results of Two Phase 1-2 Trials, Blood, 102:2684-2691.


Acute Radiation Syndrome — The symptoms, when taken together, characterize a person suffering from the effects of intense radiation. The effects occur within hours or days.

Dose Fractionation — A method of administering therapeutic radiation in which relatively small doses are given daily or at longer intervals.

Early Effects (of radiation exposure) — Effects that appear within 60 days of an acute exposure.

Late Effects (of radiation exposure) — Effects that appear 60 days or more following an acute exposure.

Radiation Absorbed Dose — The energy imparted to matter by ionizing radiation per unit mass of irradiated material at the place of interest. In SI units, the unit of radiation absorbed dose is the Gray (Gy), which is 1 J/Kg. One Gy equals 100 rads.

Radionuclide — Any radioactive isotope of an element.

Radiosensitivity — Relative susceptibility of cells, tissues, organs, organisms, or any living substance to the injurious action of radiation. Radiosensitivity and its antonym, radioresistance, are currently used in a comparative sense, rather than in an absolute one.

Therapeutic Radiopharmaceutical — A radiopharmaceutical drug product or radiobiological that is intended for use in the treatment of cancer in humans and that contains a radioactive isotope that exhibits spontaneous disintegration of unstable nuclei with the emission of nuclear radiation. The isotopes used in therapeutic radiopharmaceuticals are usually beta emitters, whereas the isotopes used in diagnostic radiopharmaceuticals are gamma emitters. Therapeutic radiopharmaceuticals are given in much higher activities and deliver much higher radiation absorbed doses than diagnostic radiopharmaceuticals.

Tracer Dose — The lowest dose based on the as-low-as-reasonably-achievable principle that will provide a diagnostic image.